Clinical study that included patients with bone fractures satisfied claim requirement for “selecting” patient with bone fractures.
December 29, 2020
Court reinstates $236 million verdict against Teva for marketing generic version of Coreg® as “AB rated”
October 18, 2020
Federal Circuit affirms PTAB decision that concentration of industrial antifungal agent in toenail fungus solution would have been obvious.
August 30, 2020
Generic competition looms for Amarin’s Vascepa (“icosapent ethyl” or “EPA”) capsules in spite of 52 patents listed in FDA’s Orange Book.
June 16, 2020
Contract requiring disputes to be adjudicated in England did not apply because it was not clear whether English Court would consider claims for U.S. patent infringement.
May 10, 2020
Federal Circuit rules that Argentum cannot pursue its appeal of a PTAB decision declining to institute an inter-partes review, even though Argentum might be estopped to challenge the patent in subsequent Hatch Waxman litigation
April 27, 2020
Federal Circuit affirms trial court decision that dose could have been arrived at by routine experimentation.
April 13, 2020
Federal Circuit affirms PTAB decision that the use of a surfactant to prevent aggregation of insulin glargine would have been obvious.
April 07, 2020